We are international
• health professionals TEXT SIZE   

Dr. Jagannath - A Phase II Study of Bortezomib (Velcade®), Cylophosphamide (Cytoxan®), Thalidomide (Thalomid®) and Dexamethasone as First-Line Therapy for Multiple Myeloma
Sundar Jagannath, MD
St. Vincent's Comprehensive Cancer Center
New York, New York
Member, IMF Board of Scientific Advisors

To view the video full screen, click on the small button next to the volume control in the lower right hand corner.

 related articles